OncoMatch/Clinical Trials/NCT06607627
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Is NCT06607627 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Gefurulimab for generalized myasthenia gravis.
Treatment: Gefurulimab — The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IV (MGFA)
Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV
Prior therapy
Cannot have received: thymectomy or any other thymic surgery
Exception: allowed if >12 months prior to Screening
History of thymectomy, or any other thymic surgery within 12 months prior to Screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Washington D.C., District of Columbia
- Research Site · Norfolk, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify